Table: Anges -2018 group results
Feb 1 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Dec 31, 2018 Dec 31, 2017 Dec 31, 2019 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 610 mln 365 mln 335 mln
(+67.1 pct) (-29.0 pct) (-45.1 pct)
Operating loss 3.07 loss 3.29 loss 2.80
Recurring loss 3.10 loss 3.31 loss 2.80
Net
Net loss 3.00 loss 3.76 loss 2.80
EPS loss 34.46 yen loss 49.38 yen loss 28.58 yen
Ann Div NIL NIL NIL
-Q2 Div NIL NIL NIL
-Q4 Div NIL NIL NIL
NOTE - Anges, Inc..
*Second Net profit row denotes profit attributable to owners ofthe parent
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001